Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma Future Oncol
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough? BRIT J HAEMATOL
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression? Int J Mol Sci
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma Front Immunol
Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018) CANCER MED-US
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials Haematologica
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy Front Immunol
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020 BRIT J HAEMATOL